Prognostic Factors in Acute Myelogenous Leukemia

  • L. Čevreska
  • R. P. Gale
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)


Recently, there has been considerable progress in the therapy of acute myelogenous leukemia (AML). Much of this progress results from the use of intensive remission induction (RI) regimens typically consisting of cytarabine and daunorubicin with or without thioguanine In recent studies, individuals who achieve a remission receive intensive post-remission chemotherapy, referred to as consolidation or intensification. Maintenance chemotherapy is also given in some studies.


Remission Rate Remission Duration Predict Treatment Outcome Premature Chromosome Condensation Antiviral Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • L. Čevreska
    • 1
  • R. P. Gale
    • 2
  1. 1.Medical FacultyUniversity of SkopjeYugoslavia
  2. 2.Department of MedicineUCLA School of MedicineLos AngelesUSA

Personalised recommendations